Premium
Featured
SwitzerTV Monday 31st March 2025
What we’re looking at buying during the Trump tariff madness
Premium
Investing
What’s my favourite buying play right now?
Like many market players, I’m hoping April 2 will bring some clarity about these Trump tariffs. Collecting a few tech companies could pay dividends by the end of this year, assuming the tariff threat becomes less uncertain. Here’s what the analysts think about our quality tech companies, and I let you know my favourite plays.
Premium
Investing
James Hardie gets clobbered. Is JHX now a buy?
James Hardie Industries (JHX) got clobbered last week, losing 20% after it announced a $14 billion takeover of The AZEK Company. Is this a buying opportunity?
Premium
Investing
HOT” stock: Macquarie Group Ltd (MQG)
In our “HOT STOCK” column today, Raymond Chan, Head of Asian Desk, explains that Macquarie Group Ltd (MQG) continues to emphasise its strong long-term structural growth potential.
Premium
Investing
Three earnings growth prospects with value
Here’s a look at three situations that look capable of producing good earnings growth this year – but there still looks to be value in the share price.
Premium
Broker Recommendations
Buy, Hold, Sell…What the Brokers Say
Ten stocks are upgraded six are downgraded
Premium
Switzer on Saturday
The Trump tariff tone will determine share prices
Overnight, Wall Street escalated its anxiety about next week’s Trump tariff revelations.
Premium
Video
Boom! Doom! Zoom! | 27th March 2025
Peter Switzer & Paul Rickard answer your questions on PME, BHP, ZIP & more
Premium
Investing
Two ETFs with exposure to the market’s best global companies.
Because there’s no substitute for quality, investors who ‘buy this dip’ should stick to the highest-quality companies that can withstand whatever Trump throws at the global economy and geopolitical landscape. Here are two ETFs that provide exposure to the market’s best global companies.
Premium
Investing
“HOT” stock: Telix Pharmaceuticals (TLX)
In our “HOT” stock article today, Michael Gable, MD of Fairmont Equities, explains that it appears as though Telix Pharmaceuticals (TLX) is back in the uptrend and current prices are a buying opportunity.